Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
Date:11/7/2013

  • Year-end cash, cash equivalents and short-term investments are expected to be in the range of $25 - $35 million.
  • Based on its current expectations, the Company believes its capital resources as of September 30, 2013 will be sufficient to fund its currently planned operations into 2015 and through the expected release of final survival results from both the Synergy and Borealis-1 trials. The cash burn is expected to be reduced in 2014 compared with 2013 because the company-sponsored Borealis-1 trial is expected to incur the majority of its costs in 2013.  Further, the investigator-sponsored OGX-427 Phase 2 trials are substantially less capital-intensive than company-sponsored trials. 
  • At November 7, 2013, The Company had 14,707,636 shares outstanding.
  •  Consolidated Statements of Loss(In thousands, except per share and share data)(unaudited)Three months ended September 30,Nine months ended September 30,2013201220132012Collaboration revenue$
    9,862$
    ,570$
    21,278$
    ,315Operating expenses:  Research and development18,00412,89542,12224,303  General and administrative2,4731,9657,4465,749Total operating expenses20,47714,86049,56830,052Loss from operations(10,615)(8,290)(28,290)(19,737)  Other income5612,3703,1192,742Net loss$
    (10,054)$
    (5,920)$
    (25,171)$
    (16,995)Basic and diluted net loss per share$
    (0.68)$
    (0.40)$
    (1.72)$
    (1.29)Weighted average number of basic and diluted common shares14,690,98414,619,84214,675,24413,141,940Consolidated Balance Sheets(In thousands) September 30,  December 31, 20132012 (unaudited) Assets:  Cash, cash equivalents, short term investments and restricted cash$
    47,091$
    75,697  Interest receivable295327  Amounts receivable9,922714  Prepaid expenses and other current assets2,7133,755  Property, equipment and other assets1,6181,523Total assets$
    ,639$
    82,016Liabilities and stockholder
    '/>"/>

    SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
    2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
    3. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
    4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
    7. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    8. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    11. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
    (Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
    (Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
    (Date:8/26/2015)... WARREN, N.J. , Aug. 26, 2015  Roka ... company focused on providing advanced testing solutions for the ... Thomas, CEO will present at the Sidoti & Company ... The conference will be held at the New York ... the presentation will be available through the investor relations ...
    Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
    ... ... in health care has always been a statement on the order of "layoffs will not ... before that is unavoidable? MedZilla.com,s monthly employment report examines that trend, as well as announcing ... ...
    ... , ... factor and how is it addressed? International Sculptra trainer Dr. Rebecca Fitzgerald, known among her ... Volume Restoration to an internationally represented group of physicians at this year,s 4 day SDEF ... ...
    ... , PALO ALTO, Calif., July 21 ... groundbreaking personal ultrasound devices, announced today it has raised US$4 ... from Australian-based venture capital firms Brandon Capital Partners, Playford Capital, ... US$13 million to date. , ...
    Cached Biology Technology:The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: June 2009 Employment Outlook for Biotech/Pharma/Health 3Looking Older Than You Are May Have Little to Do With Wrinkles 2Looking Older Than You Are May Have Little to Do With Wrinkles 3Signostics Closes Follow-On Financing of US$4 Million, Expands Board of Directors 2Signostics Closes Follow-On Financing of US$4 Million, Expands Board of Directors 3
    (Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
    (Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
    (Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
    Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
    ... BCh, of Mount Sinai Medical Center, New York was ... Genetics Fellowship in Biochemical Genetics at the ACMG 2008 ... objective of the Genzyme/ACMGF Award is to support a ... of clinicians in the field of clinical biochemical genetics ...
    ... may do it, but the microscopic animals called bdelloid rotifers ... Whats more, they have done so over millions of years ... creatures somehow escape the usual drawback of asexuality extinction ... their colleagues are finding out how. In two ...
    ... Conn.The environment will continue to deteriorate so long as ... argues Gus Speth, dean of the Yale School of ... Bridge at the Edge of the World: Capitalism, the ... Seeing an emerging environmental tragedy ...
    Cached Biology News:Is DNA repair a substitute for sex? 2Is DNA repair a substitute for sex? 3Book examines clash of capitalism and the environment 2Book examines clash of capitalism and the environment 3
    Removes polysaccharide and phenolic inhibitors of PCR; yields DNA greater than 50 kb in length...
    Sf9 Insect Cells (Frozen) in Max-XP Medium...
    HistoScan HRP Kit Universal Goat Kit...
    One bottle containing 30 ml of protein solution and 0.1% sodium azide....
    Biology Products: